Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial

Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm

FDA expands Enhertu use in early HER2-positive breast cancer

AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease

OrganaBio expands cell therapy manufacturing footprint with acquisition of Excellos Assets

The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego

Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle

This positions its platform as a rapidly evolving engine for next-generation genetic medicine

Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer

Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs

Medix Biochemica unleashes $5 million expansion to secure future of IVD supply chain

The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Teva study exposes major diagnosis gap in Tardive Dyskinesia

According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD

Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug

Baxfendy works in a fundamentally different way from current therapies

Zeus Hygia launches Metaberine in Europe and US markets

Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management